VCVildan Caner

Vildan Caner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vildan Caner has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Circulating Exosomal CD30 And CD79B in Diffuse Large B-Cell Lymphoma Patients

    by Cansu Barış Moğul, Sibel Hacıoğlu, Nilay Şen Türk, Vildan Caner, Hande Şenol

    Purpose: Up to 30-40% of patients do not respond to treatment or relapse after R-CHOP chemoimmunotherapy in DLBCL. The predictive biomarkers for identifying candidates for new therapies have not been extensively studied. We aimed to determine the presence of CD3, CD19, CD20, CD30 and CD79B in plasma-derived exosomes from DLBCL patients and to compare the profiles of target proteins in exosomes and matched primary tumour tissue. Material and Methods: Exosome samples from 20 newly diagnosed DLBCL patients and 20 healthy controls from our previous studies were characterized according to the recent MISEV2018 guidelines. The presence of targeted antibodies in exosomes was determined by Western Blotting, while their expression in primary tumour tissue was analysed by immunohistochemistry. Results: Seventeen (85%) patients had CD30-positive exosomes in their blood, while tumor cells expressing CD30 were found in only 2 (10%) patients. We only evaluated CD79B expression in tumor cells from 6 patients. Conclusion: In addition to tumor cells, characterising the factors present in the tumor microenvironment that support tumor cells, such as exosomes, will increase our success in treating DLBCL. Preclinical and clinical studies are needed to evaluate the presence of circulating CD30- and CD79B-positive exosomes in the selection of candidates for targeted immunotherapies using a non-invasive approach.

  • The PD-L1 Promoter Methylation Predicts Gene And Protein Expression Levels in Urothelial Carcinoma

    by Cansu Barış Moğul, Mesut Berkan Duran, Vildan Caner, Nilay Şen Türk, Ömer Levent Tuncay


  • Open Access

    Relationship between IL-17, TNF-α, IL-10, IFN-γ, and IL-18 polymorphisms with the outcome of hepatitis B virus infection in the Turkish population

    by Esra Nurlu Temel, Fusun Zeynep Akcam, Vildan Caner, Gülseren Bagcı, Muhammet Yusuf Tepebası

    Hepatitis B virus is a global threat that can lead to liver cirrhosis and hepatocellular carcinoma. For the treatment of chronic hepatitis B virus, polymorphisms might be an option for gene treatments. This study aimed to investigate the effects of IL-17, TNF-α, IL-10, IFN-γ, and IL-18 gene polymorphisms on hepatitis B virus infection in the Turkish population.


  • miR-21-3p and miR-192-5p in patients with type 2 diabetic nephropathy

    by Kadriye Akpınar, Diler Aslan, Semin Melahat Fenkçi, Vildan Caner

    Objectives: Microribonucleic acids (microRNA/miRNA/miR-) are predicted to be useful in the early diagnosis, monitoring, and treatment of diabetic nephropathy (DN). We aimed to investigate the relationship of DN to miR-21-3p, miR-29a-3p, miR-29b-3p, miR-29c-3p, miR-126-3p, miR-129-1-3p, miR-137, miR-192-5p, miR-212-3p, and miR-320c. Methods: There were 50 healthy controls and 100 patients with type 2 diabetes mellitus (T2DM). The diabetic patients were divided into three subgroups: normal to mildly increased (A1, n=51), moderately increased (A2, n=25), and severely increased (A3, n=24) albuminuria. The biochemical measurements were analysed using Roche Cobas 8000. The plasma miRNAs were analysed using RT-qPCR based on SYBR green chemistry. Results: The relative expression of miR-21-3p was significantly lower in the (A3 p=0.005, 6.6-fold decrease) and DN (A1 + A3) (p=0.005, 6.6-fold decrease) groups compared to the controls. The relative expression of miR-192-5p was also significantly lower in the DN group (p=0.027, 2.4-fold decrease) compared to the controls. The area under curve value was 0.726 for miR-21-3p and 0.717 for miR-192-5p for distinguishing the DN group from the controls. Conclusions: The decreased expressions of miR-21-3p and miR-192-5p are associated with the development of DN and may be potential biomarkers for the early diagnosis of DN.


  • The miRNA content of circulating exosomes in DLBCL patients and in vitro influence of DLBCL-derived exosomes on miRNA expression of healthy B-cells from peripheral blood

    by Vildan Caner, Gokhan Ozan Cetin, Sibel Hacioglu, Ikbal Cansu Baris, Emre Tepeli, Nilay Sen Turk, Gulseren Bagci, Kanay Yararbas, Gulsum Cagliyan

    BACKGROUND: Due to the heterogeneous nature of Diffuse Large B-cell Lymphoma (DLBCL), the mechanisms underlying tumor development and progression have not yet been fully elucidated. OBJECTIVE: This study aimed to compare the characteristics of plasma exosomes of DLBCL patients and healthy individuals and to evaluate the exosomal interactions between DLBCL cell lines and normal B-cells. METHODS: Exosome isolation was performed using an ultracentrifugation-based protocol from plasma of 20 patients with DLBCL and 20 controls. The expression of miRNAs from exosome samples was analyzed using a miRNA expression microarray. The presence of exosome-mediated communication between the lymphoma cells and normal B-cells was determined by the co-culture model. RESULTS: A significant increase in plasma exosome concentrations of DLBCL patients was observed. There was also a significant decrease in the expression of 33 miRNAs in plasma exosomes of DLBCL patients. It was determined that normal B-cells internalize DLBCL-derived exosomes and then miRNA expression differences observed in normal B-cells are specific to lymphoma-subtypes. CONCLUSIONS: MiR-3960, miR-6089 and miR-939-5p can be used as the miRNA signature in DLBCL diagnosis. We suppose that the exosomes changed the molecular signature of the target cells depending on the genomic characterization of the lymphoma cells they have originated.


  • Expression and DNA methylation profiles of EZH2-target genes in plasma exosomes and matched primary tumor tissues of the patients with diffuse large B-cell lymphoma

    by I. C. Barıs, S. Hacıoglu, N. S. Turk, G. O. Cetın, S. Zencır, G. Bagcı, V. Caner

    Aims Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma. This study was designed to compare epigenetic alterations observed in Enhancer of Zeste Homolog 2 (EZH2)-target genes between plasma-derived exosomes and primary tumors in DLBCL patients. Main methods Exosomes were isolated from plasma of 21 DLBCL patients and 21 controls. We analyzed the methylation status of the target genes using methylation-specific PCR. We also examined whether the exosomes and the tumor samples contained transcripts of the target genes. Key findings We found that CDKN2A and CDKN2B were methylated in both plasma exosomes and primary tumor tissue samples. None of the transcripts were found in the exosomes except CDKN1B which was expressed in 8 (38%) of the exosome samples. Significance This study showed that plasma exosomes might preferably package certain target molecules from primary tumors and the exosomes containing dual methylated DNAs of CDKN2A and CDKN2B, or CDKN1B transcript may contribute to DLBCL pathogenesis.


  • Human TLR gene family members are differentially expressed in patients with urothelial carcinoma of the bladder

    by Seda Sabah-Ozcan, Aykut Baser, Taha Olcucu, Ikbal Cansu Barıs, Levent Elmas, Levent Tuncay, Saadettin Eskicorapci, Nilay Sen Turk, Vildan Caner